Clinical Trial Update: A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating JNJ-26866138 (bortezomib) in untreated multiple myeloma patients who are not candidates for hematopoietic stem cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2013-12-02